JP2002532389A - リン脂質組成物 - Google Patents

リン脂質組成物

Info

Publication number
JP2002532389A
JP2002532389A JP2000586310A JP2000586310A JP2002532389A JP 2002532389 A JP2002532389 A JP 2002532389A JP 2000586310 A JP2000586310 A JP 2000586310A JP 2000586310 A JP2000586310 A JP 2000586310A JP 2002532389 A JP2002532389 A JP 2002532389A
Authority
JP
Japan
Prior art keywords
lipid
polymer
composition according
composition
active compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000586310A
Other languages
English (en)
Japanese (ja)
Inventor
レイ，スティーブ
レイ，マシュー・ルイス・スティーブン
Original Assignee
ファレス ファーマシューティカル リサーチ エヌブイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9827006A external-priority patent/GB2344520A/en
Priority claimed from GBGB9925365.0A external-priority patent/GB9925365D0/en
Application filed by ファレス ファーマシューティカル リサーチ エヌブイ filed Critical ファレス ファーマシューティカル リサーチ エヌブイ
Publication of JP2002532389A publication Critical patent/JP2002532389A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2000586310A 1998-12-08 1999-12-08 リン脂質組成物 Pending JP2002532389A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9827006.9 1998-12-08
GB9827006A GB2344520A (en) 1998-12-08 1998-12-08 Pharmaceutical carriers comprising lipids and polymers
GB9925365.0 1999-10-27
GBGB9925365.0A GB9925365D0 (en) 1999-10-27 1999-10-27 Phospholipid compositions
PCT/GB1999/004070 WO2000033817A1 (fr) 1998-12-08 1999-12-08 Compositions de phospholipides

Publications (1)

Publication Number Publication Date
JP2002532389A true JP2002532389A (ja) 2002-10-02

Family

ID=26314804

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000586310A Pending JP2002532389A (ja) 1998-12-08 1999-12-08 リン脂質組成物

Country Status (5)

Country Link
EP (1) EP1137402A1 (fr)
JP (1) JP2002532389A (fr)
AU (1) AU1787800A (fr)
CA (1) CA2352178A1 (fr)
WO (1) WO2000033817A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2004029104A1 (ja) * 2002-09-30 2006-01-26 日本油脂株式会社 リン脂質誘導体
JP2008255069A (ja) * 2007-04-07 2008-10-23 Yaegaki Hakko Giken Kk 機能性食品素材とその製造方法
US7867513B2 (en) 2004-02-17 2011-01-11 Eisai R&D Management Co., Ltd. Soft capsule
JP2011505158A (ja) * 2007-12-05 2011-02-24 ディーエスエム アイピー アセッツ ビー．ブイ． 脂溶性活性成分の微粉砕状調合物
JP2013543886A (ja) * 2010-11-26 2013-12-09 ユニバーシティ・オブ・ザ・ウィットウォータースランド・ヨハネスブルグ 医薬投与形態としてのポリマー−脂質ナノ粒子のポリマーマトリックス
KR20170044670A (ko) * 2014-08-29 2017-04-25 알지파마 에이에스 알기네이트 올리고머의 흡입성 분말 제형
JPWO2017061627A1 (ja) * 2015-10-09 2018-07-26 三栄源エフ・エフ・アイ株式会社 ポリフェノール含有固体組成物

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1498420B1 (fr) 2002-03-29 2017-02-01 Nof Corporation Derive phospholipidique
JP4403303B2 (ja) 2003-01-06 2010-01-27 日油株式会社 リン脂質誘導体及びその製造方法
GB0305941D0 (en) * 2003-03-14 2003-04-23 Camurus Ab Composition
WO2004083219A1 (fr) 2003-03-20 2004-09-30 Nof Corporation Derives phospholipidiques
WO2006103657A2 (fr) * 2005-03-31 2006-10-05 Dexcel Pharma Technologies Ltd. Composition solide de distribution intra-buccale d'insuline
EP1952803A1 (fr) 2007-01-23 2008-08-06 KTB-Tumorforschungs GmbH Composition pharmaceutique solide contenant des phospholipides hydrogénés
US8603568B2 (en) 2010-01-15 2013-12-10 Kemin Industries, Inc. Hydrolyzed lecithin product to improve digestibility
US10722458B2 (en) 2011-12-02 2020-07-28 Pegasus Laboratories, Inc. Amphipathic lipid-based sustained release compositions
EP3212169B1 (fr) * 2014-10-31 2021-01-13 Bend Research, Inc. Procédé de formation de domaines actifs dispersés dans une matrice
WO2021055820A1 (fr) 2019-09-20 2021-03-25 Novartis Ag Acide 3'-[(2z)-[1-(3,4-diméthylphényl)-1,5-dihydro-3-méthyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphényl]-3-carboxylique et sa formulation de sels
WO2022195545A1 (fr) 2021-03-18 2022-09-22 Novartis Ag Nouvelles formulations pharmaceutiques
CN114831128A (zh) * 2022-04-06 2022-08-02 安徽华辰检测技术研究院有限公司 一种含有苯醚甲环唑和嘧菌酯的农药制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002940A (en) * 1984-11-06 1991-03-26 Ciba-Geigy Corporation Solid drug formulations and stable suspensions
CN1065415C (zh) * 1993-02-05 2001-05-09 花王株式会社 蛋白质和类脂复合体用于改善味觉的用途
JPH06245719A (ja) * 1993-02-19 1994-09-06 Nippon Oil & Fats Co Ltd 粉末乳化剤および製造方法
JPH07291854A (ja) * 1994-04-26 1995-11-07 Tanabe Seiyaku Co Ltd 溶解性の改善された医薬品製剤
DE19531277A1 (de) * 1995-08-25 1997-02-27 Basf Ag Verwendung von Lipiden als Hilfsmittel bei der Herstellung von festen Arzneiformen nach dem Schmelzextrusionsverfahren
GB2326337A (en) * 1997-06-20 1998-12-23 Phares Pharma Holland Homogeneous lipid compositions for drug delivery

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2004029104A1 (ja) * 2002-09-30 2006-01-26 日本油脂株式会社 リン脂質誘導体
JP4808403B2 (ja) * 2002-09-30 2011-11-02 日油株式会社 リン脂質誘導体
US7867513B2 (en) 2004-02-17 2011-01-11 Eisai R&D Management Co., Ltd. Soft capsule
JP2008255069A (ja) * 2007-04-07 2008-10-23 Yaegaki Hakko Giken Kk 機能性食品素材とその製造方法
JP2011505158A (ja) * 2007-12-05 2011-02-24 ディーエスエム アイピー アセッツ ビー．ブイ． 脂溶性活性成分の微粉砕状調合物
JP2013543886A (ja) * 2010-11-26 2013-12-09 ユニバーシティ・オブ・ザ・ウィットウォータースランド・ヨハネスブルグ 医薬投与形態としてのポリマー−脂質ナノ粒子のポリマーマトリックス
KR20170044670A (ko) * 2014-08-29 2017-04-25 알지파마 에이에스 알기네이트 올리고머의 흡입성 분말 제형
KR102582982B1 (ko) 2014-08-29 2023-09-25 알지파마 에이에스 알기네이트 올리고머의 흡입성 분말 제형
JPWO2017061627A1 (ja) * 2015-10-09 2018-07-26 三栄源エフ・エフ・アイ株式会社 ポリフェノール含有固体組成物

Also Published As

Publication number Publication date
WO2000033817A1 (fr) 2000-06-15
EP1137402A1 (fr) 2001-10-04
CA2352178A1 (fr) 2000-06-15
AU1787800A (en) 2000-06-26

Similar Documents

Publication Publication Date Title
JP2002532389A (ja) リン脂質組成物
EP2200588B1 (fr) Compositions comprenant des composés actifs lipophiles et procédé pour leur préparation
JP5240822B2 (ja) 多孔質セルロース凝集体及びその成型体組成物
EP0235986B2 (fr) Formulation à libération lente
JP4969104B2 (ja) 多孔質セルロース凝集体及びその成型体組成物
JP3725539B2 (ja) ビサコジル剤形
EP3154529B1 (fr) Comprimé oraux à désintégration rapide contenant des particules lipidiques solides, et procédé de préparation et méthode d'utilisation de celui-ci
EP1722821B1 (fr) Composition destinee a l'administration orale d'hydrochlorure de tamsulosine et formulation en granules a liberation controlee comprenant cette composition
KR101434334B1 (ko) 화학 물질의 마이셀 나노입자
US7655697B2 (en) Oral pharmaceutical composition for targeted transport of a platinum complex into the colorectal region, method for producing and use as medicament thereof
JP2010525082A (ja) 固体投与形
JP2003531849A (ja) グアイフェネシン徐放製剤および錠剤
JP2006316076A (ja) スルホアルキルエーテルシクロデキストリンを基剤とする放出制御固形医薬製剤
JPH07291854A (ja) 溶解性の改善された医薬品製剤
EP3996695A1 (fr) Comprimés de cannabidiol à désintégration orale
EP0018773A1 (fr) Composition pharmaceutique contenant du fumarate de bencyclane, un procédé pour sa préparation et un composé d'inclusion contenant le fumarate de bencyclane
US8962017B2 (en) Formulation of silymarin with high efficacy and prolonged action and the preparation method thereof
JP2008525389A (ja) 活性成分移送のための新規ガレン製剤系、その製造方法および用途
CN101600439B (zh) 甘草酸或其盐的口服药物组合物及其制备方法
US20110311625A1 (en) Solid dosage forms of fenofibrate
EP0914822A1 (fr) Preparation d'ecadotril a microdispersion et liberation rapides
JP2511577B2 (ja) アルギン酸プロピレングリコ―ルエステルからなる徐放性製剤
WO2005049048A1 (fr) Fraction riche en fibres de trigonella foenum-graecum et son utilisation comme excipient de qualite pharmaceutique
CN101686946A (zh) 化学物质的胶束纳米颗粒
CA2253769C (fr) Composes pharmaceutiques a base de fenofibrate